CTLA4 and melanoma: In patients treated with an anti–CTLA-4 therapy, the biomarker score remained predictive of OS across clinical subgroups, including male, female, and melanoma (HRs <1; Supplementary Fig. S5E), suggesting that its prognostic value is likely robust in these cohorts.